Press release
Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
A lawsuit was filed on behalf of investors in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shares.
Investors who purchased shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) have certain options and for certain investors are short and strict deadlines running. Deadline: February 7, 2025. NASDAQ: KYTX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Emeryville, CA based Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead product candidate is KYV-101.
In early February 2024, Kyverna Therapeutics, Inc conducted its initial public offering (IPO). Kyverna Therapeutics, Inc sold over 16 million shares at $22 per share. Since then shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) declined to as low as $3.94 per share on November 19, 2024.
The plaintiff claims that the registration statement and prospectus used to effectuate the Company's IPO misstated and/or omitted facts concerning the results of the Company's ongoing evaluation of KYV-101 in clinical trials, that the Company touted patient "improvement" in certain indicators while failing to disclose adverse data regarding one of Kyverna's trials, which adverse data was known to the Company at the time of the IPO, and that as a result, investors purchased Kyverna shares at artificially inflated prices.
Those who purchased shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) here
News-ID: 3847903 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of West Pharmaceutical Se …
An investor, who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST), filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania over alleged violations of Federal Securities Laws by West Pharmaceutical Services, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST) have certain options and for certain investors are short and strict deadlines running.…
enCore Energy Corp. (NASDAQ: EU) Long Term Investor Investigation of potential W …
An investigation on behalf of current long-term investors in shares of enCore Energy Corp. (NASDAQ: EU) concerning potential breaches of fiduciary duties by certain directors and officers of enCore Energy Corp. was announced.
Investors who are current long term investors in enCore Energy Corp. (NASDAQ: EU) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for…
Sana Biotechnology, Inc. (NASDAQ: SANA) Investor Alert: Deadline in Lawsuit on M …
A deadline is coming up on May 20, 2025 in the lawsuit filed for certain investors of Sana Biotechnology, Inc. (NASDAQ: SANA) over alleged securities laws violations by Sana Biotechnology, Inc.
Investors who purchased shares of Sana Biotechnology, Inc. (NASDAQ: SANA) have certain options and there are strict and short deadlines running. Deadline: May 20, 2025. Sana Biotechnology, Inc. (NASDAQ: SANA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Investors who hold shares of e.l.f. Beauty, Inc. (NYSE: ELF) Long Term should co …
An investigation was announced for long-term investors in shares of e.l.f. Beauty, Inc. (NYSE: ELF) concerning potential breaches of fiduciary duties by certain directors of e.l.f. Beauty, Inc.
Investors who are current long term investors in e.l.f. Beauty, Inc. (NYSE: ELF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
More Releases for Kyverna
Synthetic Biology Market Trends, Future Outlook, COVID-19 Impact Analysis, Forec …
The global synthetic biology market is anticipated to grow at a considerable CAGR of 32.0% during the forecast period (2022-2028). The growing involvement and assistance from government bodies in synthetic biology research activities will likely support the market during the forecast year. Governments of various nations are providing research support for synthetic biology due to its extensive applications in chemical environmental, agriculture, medical, energy, nanotechnology and others. For instance, in…
